Home
Search
Study Topics
Glossary
|
Study 3 of 677 for search of: | received on or after 04/22/2009 |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00886600 |
The purpose of this study was to evaluate the magnitude and durations of the antihypertensive effects of losartan using ambulatory blood pressure monitoring, and to evaluate the safety of losartan 50 and 100 mg doses compared to placebo.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: losartan potassium Drug: Comparator: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Pilot Study to Investigate the Magnitude and Duration of Response and the Safety of MK0954 (50 mg Given Once or Twice Daily, or 100 mg Given Once Daily) Compared to Placebo Using Ambulatory Blood Pressure Monitoring |
Enrollment: | 122 |
Study Start Date: | May 1991 |
Study Completion Date: | August 1992 |
Primary Completion Date: | May 1992 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator
Placebo
|
Drug: Comparator: placebo
two placebo capsules to MK0954 administered twice daily for four weeks
|
2: Experimental
MK0954 50 mg QD
|
Drug: losartan potassium
two capsules (50 or 100 mg) administered twice daily for four weeks
|
3: Experimental
MK0954 100 mg QD
|
Drug: losartan potassium
two capsules (50 or 100 mg) administered twice daily for four weeks
|
4: Experimental
MK0954 50 mg BID
|
Drug: losartan potassium
two capsules (50 or 100 mg) administered twice daily for four weeks
|
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2009_581, MK0954-021 |
Study First Received: | April 22, 2009 |
Last Updated: | April 22, 2009 |
ClinicalTrials.gov Identifier: | NCT00886600 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Angiotensin II Type 1 Receptor Blockers Losartan Vascular Diseases Cardiovascular Agents |
Anti-Arrhythmia Agents Angiotensin II Antihypertensive Agents Hypertension |
Angiotensin II Type 1 Receptor Blockers Losartan Molecular Mechanisms of Pharmacological Action Therapeutic Uses Vascular Diseases Cardiovascular Diseases |
Cardiovascular Agents Anti-Arrhythmia Agents Antihypertensive Agents Pharmacologic Actions Hypertension |